Castle Biosciences, Inc.

Castle Biosciences, Inc. is a **molecular diagnostics company** specializing in genomic tests that inform clinical decision-making in dermatology, ophthalmology, and gastroenterology. Its portfolio includes proprietary gene expression profile assays such as DecisionDx-Melanoma and DecisionDx-SCC, which assess metastatic risk in skin cancers, DecisionDx-UM for uveal melanoma staging, MyPath Melanoma for lesion characterization, and TissueCypher for predicting progression risk in Barrett’s esophagus. The company’s tests aim to provide **personalized, clinically actionable insights** by analyzing tumor biology, helping clinicians refine treatment planning, surveillance strategies, and biopsy decisions. Castle Biosciences reports extensive clinical validation, citing more than 150 peer-reviewed publications and over 300,000 test reports delivered since 2008, underscoring its role in precision medicine for cancer and pre-cancer management. Founded in 2008 and public since 2019, Castle Biosciences focuses on improving outcomes through innovation, AI-enabled analytics, and real-world evidence generation, with growing adoption reflected in rising test volumes and revenue. The company serves physicians and patients across specialty care settings where risk stratification and individualized prognostics are critical.